

Apr 22, 2024

## Mitochondrial DNA base editing in HEK293T cells

DOI

**dx.doi.org/10.17504/protocols.io.yxmvm3rnl3p/v1**

Nicole Lake<sup>1</sup>, Kaiyue Ma<sup>1</sup>, Justin Cohen<sup>1</sup>, Monkol Lek<sup>1</sup>

<sup>1</sup>Department of Genetics, Yale School of Medicine, New Haven, CT, USA.

Lek Lab



**Justin Cohen**  
Yale School of Medicine

OPEN  ACCESS



DOI: [dx.doi.org/10.17504/protocols.io.yxmvm3rnl3p/v1](https://dx.doi.org/10.17504/protocols.io.yxmvm3rnl3p/v1)

**Protocol Citation:** Nicole Lake, Kaiyue Ma, Justin Cohen, Monkol Lek 2024. Mitochondrial DNA base editing in HEK293T cells. protocols.io <https://dx.doi.org/10.17504/protocols.io.yxmvm3rnl3p/v1>

**Manuscript citation:**

Lake NJ, et al. Quantifying constraint in the human mitochondrial genome. bioRxiv (2023). <https://doi.org/10.1101/2022.12.16.520778>

**License:** This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** Working

**We use this protocol and it's working**

**Created:** February 12, 2024

**Last Modified:** April 22, 2024

**Protocol Integer ID:** 95136

**Keywords:** DdCBE, Base Editor, Mitochondria, Transfection, HEK293

## Abstract

This protocol is for the transfection of mitochondrial-targeted DddA-derived cytosine base editors (DdCBE), and their subsequent selection, in HEK293T cells. This uses a dual plasmid system, where a 'left' and 'right' DdCBE are needed for editing. Enrichment of cells with both DdCBE halves is achieved by separate drug selection for the left and right plasmids.

## Materials

HEK293 cells (ATCC, CRL-3216)

HEK media

- DMEM (Gibco, 11965092)
- 10% FBS (R&D Systems S11150)
- No antibiotics

DdCBE plasmids:

- Left/left-dead (blastR) and Right (PuroR)

Lipofectamine 3000 reagents (ThermoFisher, L3000008)

Opti-Mem I reduced serum medium (ThermoFisher, 31985070)

12-well tissue culture plates (Corning, 353043)

Blasticidin (ThermoFisher, A1113903)

Puromycin (ThermoFisher, A1113803)

## Protocol materials

⊗ Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070** In 2 steps

⊗ HEK293T **ATCC Catalog #CRL-3216** Step 1

⊗ Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903** In 2 steps

⊗ Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008** In 3 steps

⊗ Falcon® 12-well Clear Flat Bottom TC-treated Multiwell Cell Culture Plate, with Lid, Individually Wr **Corning Catalog #353043**

Step 1.2

⊗ Right DdCBE Plasmid **addgene Catalog #179686** Step 2.2

⊗ Left DdCBE Plasmid **addgene Catalog #179682** Step 2.2

⊗ Left Dead (inactive) DdCBE Plasmid **addgene Catalog #179683** Step 2.2


⊗ Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803** In 2 steps

⊗ DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** In 4 steps

⊗ Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** In 4 steps




## Plating of the HEK293T Cells

1 Plating of  HEK293T **ATCC Catalog #CRL-3216**


1.1 The day before transfection, trypsinize and count the cells.

1.2 In a

 Falcon® 12-well Clear Flat Bottom TC-treated Multiwell Cell Culture Plate, with Lid, Individually Wr **Corning Catalog #353043**



, plate 150000 cells per well in  1 mL per well of complete HEK media (

 DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with

[M] 10 % volume  Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without antibiotics).


### Note


Antibiotics can reduce transfection efficiency and were thus omitted.


1.3 Wait for cells to attach  Overnight at  37 °C in a 5% CO<sub>2</sub> tissue culture incubator.

## Transfection of DdCBE Plasmids

2 Transfection of DdCBE Plasmids

2.1 For each well of cells to be transfected, dilute  3 µL of






 Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

into  50 µL (total volume) of

 Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070**

and mix well.



- 2.2 In a separate tube, for each well of cells to be transfected, dilute  2  $\mu\text{g}$  of each DdCBE plasmid  Left DdCBE Plasmid **addgene Catalog #179682** or  Left Dead (inactive) DdCBE Plasmid **addgene Catalog #179683** with  Right DdCBE Plasmid **addgene Catalog #179686** that had been modified to include PuroR marker (left and right, for total of  4  $\mu\text{g}$  plasmid DNA (pDNA))


#### Note

The DdCBE plasmids used were obtained from Addgene, which included left (Addgene #179682) and right (Addgene #179686) DdCBE plasmids for editing, and a left dead (i.e. inactive) DdCBE plasmid (Addgene #179683) used with the right as a control. For this protocol, the right DdCBE plasmid was modified by replacing the *BSD* gene with *PuroR* to enable dual selection. Please see the associated publication for more plasmid details.

into  50  $\mu\text{L}$  (total volume) of


 Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070** .

Then add  8  $\mu\text{L}$  P3000 Reagent from

 Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**


(a 2:1 ratio to DNA) directly to the diluted pDNA. Mix well.

- 2.3 Add the diluted pDNA solution in P3000 reagent (from 2.2) to diluted


 Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

(from 2.1), mix, and incubate for  00:15:00 min at room temperature.


15m

- 2.4 Discard the old medium in the well. Add  1 mL complete HEK media (

 DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with

[M] 10 % volume  Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without

antibiotics) to each tube, mix well, and add to the corresponding well. Do this step well by well.












Incubate the cells at  37 °C in a 5% CO<sub>2</sub> tissue culture incubator.

## Selection of the Transfected Cells

18h

- 3 Selection of the Transfected Cells



- 3.1  18:00:00 hrs later, replace the medium with complete HEK media ( 18h
-  DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with
- [M] 10 % volume  Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without
- antibiotics) containing up to  5 ug/mL of
-  Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903** and  1 ug/mL of
-  Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803**
- 3.2 Continue selection for 10-14 days and replace the medium every 2 days with complete HEK media containing  Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903** and
-  Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803** . Ensure drug selection is not finished until all the control untransfected cells are dead. Passage the cells to a larger well-size or flask if needed.
- 3.3 Once selection is finished, maintain the cells in complete HEK media (
-  DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with
- [M] 10 % volume  Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without
- antibiotics) for at least 2 days before performing any experiments.

## Protocol references

Protocol adapted from Mok, B.Y., et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. *Nature* 583, 631–637 (2020), and Mok, B.Y., et al. CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA. *Nat Biotechnol* 40, 1378–1387 (2022).